Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Acrigen Biosciences logo — Developing life-saving genetic therapies using our proprieta...

Acrigen Biosciences

Developing life-saving genetic therapies using our proprietary precision gene editing technology

Founded 2019 United States Alameda, United States 6 employees Seed Total: $1.23M Biotechnology, Life Sciences

General Information

Company Name Acrigen Biosciences
Founded Year 2019
Location United States Alameda, United States
Employees 6
Industries Biotechnology, Life Sciences
Funding Stage Seed
Business Model B2B, Platform
Revenue Model Licensing, Project Based
Social

BounceWatch is an independent company data service, not affiliated with Acrigen Biosciences. To contact Acrigen Biosciences, visit acrigen.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Acrigen Biosciences compare?

A PDF of Acrigen Biosciences and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Acrigen Biosciences soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Acrigen Biosciences

Acrigen Biosciences, founded in 2019, is a pioneering life science startup based in Berkeley, California. With a focus on biotechnology and life sciences, the company stands out for its mission to develop life-saving genetic therapies using its proprietary precision gene editing technology.

Co-founded by Dr. Joseph Bondy-Denomy and Dr. David Rabuka, Acrigen Biosciences is harnessing novel CRISPR-Cas gene editors alongside anti-CRISPR proteins to enhance the precision, efficacy, and safety of genetic therapies. Dr. Bondy-Denomy is notably credited with the discovery of anti-CRISPR proteins, lending robust scientific credibility to the company’s innovations.

In February 2022, Acrigen Biosciences received a $1.00M grant investment from the National Science Foundation, underscoring the potential impact of its platform. As an early-stage company, it presents a captivating opportunity for investors aiming to support advancements in genetic therapies that could revolutionize treatment paradigms for genetic disorders.

Business keywords: gene editing, CRISPR-Cas technology, genetic therapies, anti-CRISPR proteins, precision medicine, genetic disorders, life sciences, therapeutic pipeline, biomedical innovation, safety enhancement, efficacy improvement, novel biotechnologies, disease prevention

Services & Products

Development of Precision Gene Editing Systems
Licensing of CRISPR-Cas Nuclease Library
ErAcr Proteins for Precision Enhancement

Target Customers

Biopharmaceutical Companies Medical Research Institutions Healthcare Providers Biotechnology Firms

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Grant $1.00M 1
National Science Foundation
National Science Foundation
01 Feb 2022
Seed Undisclosed 4
Dolby Ventures Alexandria Venture Investments Berkeley Catalyst Fund
Dolby Ventures, Alexandria Venture Investments +2
01 Sep 2021
Grant $230.00K 1
National Science Foundation
National Science Foundation
01 Sep 2020
Spinout Undisclosed 1
University of California, Berkeley
01 Dec 2019

Acrigen Biosciences Alternatives & Competitors

View All Alternatives
Acrigen Biosciences vs
Modalis Therapeutics
Modalis Therapeutics United States

Modalis is an emerging biotech company that develops therapeutics using CRISPR based technology

IPO
23 employees
Biotechnology, Health Care
Acrigen Biosciences vs
Prime Medicine, Inc.
Prime Medicine, Inc. United States

Delivering on the promise of Prime Editing

IPO
184 employees
Biotechnology, Life Sciences
Acrigen Biosciences vs
Moonwalk Biosciences
Moonwalk Biosciences United States

Pioneering novel therapeutics in adipose biology and tissue, driven by deep genetic and epigenetic i...

Series A
21 employees
AI, Biopharma
Also compare with: Acrigen Biosciences vs HuidaGene Therapeutics HuidaGene Therapeutics View all alternatives

FAQ About Acrigen Biosciences

Developing life-saving genetic therapies using our proprietary precision gene editing technology
Acrigen Biosciences was founded in 2019.
Acrigen Biosciences is headquartered in Alameda, United States.
Acrigen Biosciences operates in Biotechnology and Life Sciences. Its work centres on gene editing, CRISPR-Cas technology, genetic therapies and anti-CRISPR proteins. Its customers include Biopharmaceutical Companies, Medical Research Institutions and Healthcare Providers.
Acrigen Biosciences has a B2B and Platform business model. Its revenue comes from Licensing and Project Based.
Acrigen Biosciences has approximately 6 employees.
Acrigen Biosciences has completed 4 funding rounds, raising a total of $1.23M. The latest funding stage is Seed.
Acrigen Biosciences offers: Development of Precision Gene Editing Systems, Licensing of CRISPR-Cas Nuclease Library, ErAcr Proteins for Precision Enhancement.
Top alternatives and competitors to Acrigen Biosciences include Modalis Therapeutics, Prime Medicine, Inc., Moonwalk Biosciences, Tessera Therapeutics, G+FLAS Life Sciences, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Acrigen Biosciences and Modalis Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Acrigen Biosciences, https://bouncewatch.com/company/acrigen-biosciences, updated 9 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout